<DOC>
	<DOCNO>NCT02466958</DOCNO>
	<brief_summary>The purpose study examine effect levomilnacipran ( FETZIMA ) compare placebo treatment depression old adult .</brief_summary>
	<brief_title>Trial Levomilnacipran Geriatric Depression</brief_title>
	<detailed_description>A 12-week pilot double-blind comparison levomilnacipran ( FETZIMA ) placebo treatment geriatric depression . The investigator interested assess efficacy levomilnacipran ( LMIL ) placebo ( PBO ) , explore effect antidepressant response brain connectivity neuroplasticity . This pilot study design determine difference efficacy , safety tolerability levomilnacipran compare placebo , perform dose find ( 20-120 mg per day ) 60 old depress adult . The investigator anticipate LMIL superior PBO improving level depressive symptom rate remission , well improve cognition , apathy , quality life . This proposal expand investigator 's focus biomarkers neuroplasticity use several prior study demonstrate responsivity antidepressant treatment . The purpose examine directly 60 old adult major depression . This propose trial also serve pilot study estimate efficacy tolerability drug old depressed adult , dose-finding population .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>60 year age older The presence major depressive disorder diagnose accord DSMV criteria A 24item Hamilton Rating Scale Depression ( HAMD ) score 17 high baseline MiniMental State Exam ( MMSE ) score &gt; 24 . Subjects exclude 1 ) current and/or lifetime history psychiatric disorder ( except unipolar depression without comorbid generalize anxiety disorder ) , 2 ) recent unstable medical neurological disorder ; 3 ) disability prevent participation study MRI ; 4 ) diagnosis dementia ; 5 ) acute suicidality ; 6 ) subject know allergic reaction milnacipran , uncontrolled narrow angle glaucoma , seizure , poorlycontrolled hypertension ischemic change ECG , serotonin syndrome , recently use MAOIs within last 4 week ; 7 ) ineligible MRI ( e.g. , metal body claustrophobia )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>depressed</keyword>
	<keyword>old adult</keyword>
	<keyword>antidepressant</keyword>
	<keyword>depression</keyword>
	<keyword>MDD</keyword>
</DOC>